A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Meniere's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Latanoprost (Primary)
- Indications Meniere's disease
- Focus Therapeutic Use
- Sponsors Synphora
- 19 Jun 2016 Status changed from active, no longer recruiting to completed.
- 16 Mar 2016 Phase of the study changed from phase II/III to phase II, according to ClinicalTrials.gov record.
- 16 Mar 2016 Planned primary completion date changed from 1 Oct 2014 to 1 May 2016, according to ClinicalTrials.gov record.